Increased risks of psychiatric disorders in patients with primary Sjögren's syndrome-a secondary cohort analysis of nationwide, population-based health claim data.
Anxiety
Depression
Primary Sjögren’s syndrome
Sleep disorder
Journal
Clinical rheumatology
ISSN: 1434-9949
Titre abrégé: Clin Rheumatol
Pays: Germany
ID NLM: 8211469
Informations de publication
Date de publication:
Nov 2019
Nov 2019
Historique:
received:
18
02
2019
accepted:
19
07
2019
revised:
24
06
2019
pubmed:
3
8
2019
medline:
31
3
2020
entrez:
3
8
2019
Statut:
ppublish
Résumé
Primary Sjögren's syndrome (pSS) is a chronic systemic autoimmune disease. The aim of this study was to investigate the risk of five common psychiatrist-diagnosed disorders in patients with pSS. Using Taiwan's National Health Insurance Research Database, 688 patients with newly diagnosed pSS between 2000 and 2012 were identified. Two comparison cohorts were assembled, namely, 3440 patients without pSS and 1302 newly diagnosed patients with rheumatoid arthritis. The incidences of depressive disorder, anxiety disorder, bipolar disorder, sleep disorder, and schizophrenia between the pSS cohort and the comparison cohorts were compared using Poisson regression models. Patients with pSS exhibited a significantly higher risk of developing depressive disorder (adjusted incidence rate ratio [aIRR] = 2.11, p < 0.001), anxiety disorder (aIRR = 2.20, p < 0.001), and sleep disorder (aIRR = 1.76, p = 0.012) when compared with the non-pSS cohort. The risks of developing depressive, anxiety, and sleep disorders were also significantly increased when compared to the rheumatoid arthritis comparison cohort. When the analyses were stratified by sex, depressive disorder (aIRR = 2.10, p < 0.001), anxiety disorder (aIRR = 2.02, p = 0.001), and sleep disorder (aIRR = 1.74, p = 0.022) were found to be significantly increased in female patients with pSS. However, only anxiety disorder (aIRR = 4.88, p = 0.044) was also significantly increased in male patients with pSS. The peak age group of developing depressive disorder was 65-80 years old (aIRR = 3.46, p < 0.001). In this retrospective cohort study based on population-based claim data, significantly increased incidences of depressive disorder, anxiety disorder, and sleep disorder were observed in patients with pSS. Key Points • Patients, particularly women, with primary Sjögren's syndrome exhibited a significantly higher risk of developing depressive disorder, anxiety disorder, and sleep disorder. • The peak age group of developing depressive disorder was 65-80 years old.
Identifiants
pubmed: 31372849
doi: 10.1007/s10067-019-04705-z
pii: 10.1007/s10067-019-04705-z
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
3195-3203Références
J Rheumatol. 2015 Jul;42(7):1203-8
pubmed: 25979721
Brain Behav Immun. 2017 May;62:212-218
pubmed: 28161475
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Joint Bone Spine. 2016 Dec;83(6):681-685
pubmed: 26774177
Nucl Med Commun. 2000 Jan;21(1):31-5
pubmed: 10717899
Psychiatry Clin Neurosci. 2019 Jun;73(6):302-316
pubmed: 30719813
Ann Rheum Dis. 2010 Jun;69(6):1103-9
pubmed: 19561361
Clin Exp Rheumatol. 1997 Jan-Feb;15(1):71-4
pubmed: 9093776
Lancet Psychiatry. 2017 Feb;4(2):146-158
pubmed: 27856392
J Rheumatol. 2010 Jun;37(6):1188-94
pubmed: 20360180
Arthritis Rheum. 1993 Mar;36(3):340-7
pubmed: 8452579
Lancet Psychiatry. 2017 Jan;4(1):73-82
pubmed: 27856395
J Rheumatol. 2016 Mar;43(3):625-31
pubmed: 26834219
Am J Psychiatry. 2006 Mar;163(3):521-8
pubmed: 16513876
J Affect Disord. 2018 Feb;227:31-37
pubmed: 29049933
Neuropsychiatr Dis Treat. 2016 Mar 22;12:661-3
pubmed: 27042076
Eye (Lond). 2016 Dec;30(12):1558-1567
pubmed: 27518547
Clin Immunol. 2016 Apr;165:60-7
pubmed: 26995659
Annu Rev Public Health. 2013;34:119-38
pubmed: 23514317
Int J Mol Sci. 2018 Dec 08;19(12):
pubmed: 30544839
Lupus. 2018 Oct;27(1_suppl):32-35
pubmed: 30452329
J Rheumatol. 2011 Apr;38(4):706-8
pubmed: 21239759
Lancet. 2005 Jul 23-29;366(9482):321-31
pubmed: 16039337
Psychol Health Med. 2018 Feb;23(2):198-209
pubmed: 28621153
Ann Rheum Dis. 2002 Jun;61(6):554-8
pubmed: 12006334
Ann Rheum Dis. 2011 Jun;70(6):968-72
pubmed: 21345815
Rheumatology (Oxford). 2017 Apr 1;56(4):570-580
pubmed: 28013207